NKTR-255 in combination with durvalumab following chemoradiation was well-tolerated in patients with non–small cell lung ...

Against a backdrop of rising demand, with the amount of mobile data consumed by its mobile communications customers having been measured to have increased by 26% in 2023, Virgin Media O2 (VMO2) has ...

These are independent reviews of the products mentioned, but TIME receives a commission when purchases are made through ...

This trial will assess an individualized neoantigen therapy plus Keytruda in some patients with non-small cell lung cancer.

After launching their commercial 5G Standalone (SA) mobile network during February 2024 (here), O2 (Virgin Media) has today ...

Virgin Media O2 has deployed what it claims to be the UK's first 5G Standalone (5G SA) small cells. In an announcement today ...

The top stories in non-small cell lung cancer (NSCLC) for 2024 included practice-changing results in EGFR-mutant disease, an ...

On November 1, Shenzhen Chipscreen Biosciences Co., Ltd. (hereinafter referred to as 'Chipscreen Biosciences') and its wholly-owned subsidiary Chengdu Chipscreen Pharmaceutical Ltd., received the ...

Study results show that a portable breath analysis device designed for early detection of non–small cell lung cancer may distinguish between patients with the disease and healthy individuals.

In operable non-small cell lung cancer (NSCLC), molecular residual disease (MRD) detection via circulating tumor DNA (ctDNA) ...

The 22nd Annual Winter Lung Cancer Conference, January 31-February 2, 2025, will cover advances in NSCLC and SCLC treatment.